Geoffrey Klass, Sense Neuro Diagnostics - Non-Invasive Brain Scanners | LSI USA '24

Geoffery Klass  0:04  
Sense Neuro Diagnostics we have, it's a platform technology to detect, measure and monitor neurological disorder of the brain. But the first application of that technology is for stroke and traumatic brain injury patients. Because it's this is often news time, his brain for those people, every minute of delay to treatment, millions of brain cells are dying. And the problem is there really is no technology to triage these people effectively in the field, nor to monitor their condition and the neuro ICU. And these are people that have to be detected and getting treatment in a measurement of minutes and seconds and not hours. The problem is huge. You've seen a lot of these numbers, the burden on their US healthcare system is over $300 billion a year, the number of misdiagnosed patients in the ER in the US 40 to 80,000 patients a year, worldwide one to 30 and that's probably an underestimate, have access to any sort of imaging equipment. And military TBI is the signature wound today. So when we developed our product, we knew we had to get a few things. We talked to people in the military and physicians and hospitals and, and EMS people and figured out, you know, what do we need, we need to have something that's multifunctional, be able to detect more than one things, you know, be extremely accurate, we're at 95% sensitivity already. And that's only going to improve, we needed to have absolute full brain coverage all the way through deep structures into the into the brainstem, it had to be fast, simple, no technical skills, and have real flexibility and design because everybody wants it own different twist, and then really make it cheap. So we've come up with this, and this is one sample this our neuro Hawk device. And the way this works is we use radio frequency. So our radio waves are one 500 out of a cell phone, so it's a really low power. But these radio waves, nine of them send a receive to each other. And normal brain tissue gives off a signal ischemic tissue where there is no blood gives off a different signal. And then bleeding gives off a third algorithms child calculate the change in signal. And for that, we're able to determine what's going on to that patient's brain. And as you can see here, we could see bleeds as small as a half an ML, so that's like a half of a green pea. So we're very good in what we're able to see. And importantly, most importantly, we could see stroke by subtype, which is very important in order to get the person to the right place for treatment. We have three devices they all use the exact same technology form really is for function. So this is the adaptability in our design. Take a little deep dive. So the new stat device will be used in the neuro ICU to monitor those stroke. TBI patients or anyone who is susceptible to an expanded brain bleed will scan every minute. And if something begins to happen, we pick it up right away and alarm. Right now these patients are subjectively assessed every hour. For the neuro Hawk EMS and er device. This again, we needed to get something no technical skills required. You need to be able to just put it on and turn it on. So EMS personnel, they get a patient they put it on they turn it on, and in less than five minutes. They know if they're having a stroke, but more importantly, what type of stroke it is. Or if it's TBI patient, do they have a bleed associated with it? In the ER, they have five minutes to to triage your patient. So we had to operate within that period of time. Someone comes in with the triage nurse, you just slip this on their head and turn it on that's it, and then do everything else you need to triage that patient. By the time you're done with your five minutes. You have blood pressure, you know what's going on inside their head, and you have a history so it operates very, very quickly. And then neuro Hawk military, there is no technology and fire forwarded environments to assess TBI patients. So we created again, no technical skills required. They say that give it something give us something that can be operated by somebody who has no more than a high school education. So it really works like this. Just slip it on you turn it on. And if you see the three LED lights, if we get a green light, he's okay. You the yellow light means the system is working properly or not. If you get a red light floods present, if the red light flashes bleeds expanding, and it flips into monitoring mode stays with the warfighter until they evacuate that person into a field hospital. So lightweight, easy to use. And if you have multiple casualties, a medic is very efficient. You put one on everybody's head, and then you just read what you've got. So it's very effective in that environment. Ultimately, aside from those three here As we will be in nursing homes where Falls is one of the biggest problems they have urgent care facilities have no technology whatsoever. physician's offices and obviously athletics. The market US markets huge triage is about $2 billion. The military market, we see about 200 million in hospital monitoring, again 200 million, and then that all of our market is well over 2 billion, where we sit right now, new stat neuro Hawk, we've just finished our clinical trials, we're going to be filing with the FDA in a couple of months. And we will have these two vices devices cleared by the end of this year. So we're very close. Let me just give a shout out to our M Tech partnership, if you aren't a member become a member, they have been so helpful with our company as we have grown, as you could see, we've gotten about nine or $5 million dollars in non dilutive funding of various types. But it's not only the DoD relationship they help you with. The important part is they see, we need to be successful commercially, in order to best support what we're going to do for the Department of Defense. And they have been a fabulous partner with us doing that quick competitive overview of our technology versus rest of market, you know that the advantages are easy, we detect all three stroke subtypes bleeding, we're very fast we monitor we're accurate, very cost effective. And it doesn't take any training to slip it on and turn it on. Financially, you know, won't go through this, but we begin making money next year. And that's a great thing for us. So current investment, we do have a $4 million round that's open. And this finishes up all we need to take us through FDA clearance and begin to launch ourselves commercially. We have a million and a half of that in very comfortable that the other two and a half, this has been a successful meeting for us. We'll be coming in probably by the end of April, we should be finished. And then there's a $2 million grant. This we now have have been awarded and we're in contracting with the DOD for that. We also have another great partnership with the Mayo Clinic where their accelerator program, when you're in that you have disposal of any physician, business person researcher at the Mayo Clinic to work with you. And they have been working with us and all three of our devices. And then future development as we move off to concussion. We have a great team, cipher myself, Dr. AdAway, corfac, and Shawn flattery. They're the founders. We have Eric Bailey, who's just joined us quick about Eric. He's the one who invented that scanner that your luggage goes through at the airport. But he also developed the portable CAT scan. And he also developed the mobile stroke unit. And he sees that we absolutely have to get our product to market. And he's committed to do that. We also have a really great extended team. And if you're around a 1245, please come to our presentation. But we have Mike Singletary with us, Dr. Hunt    Batjer. And then we also have Dr. Bernard    Bendok. coming with us today to talk about the future of innovation to treat stroke and traumatic brain injury patients. It's going to be a great session. And then finally, you know, why would somebody want to invest in us, we've got our devices clearing FDA, at the end of this year. We're going commercial, we're really excited about that. But that's really the beginning of where we go. So after that, that platform technology, we begin to move into caution for assessment and monitoring. We already have a patent for sudden cardiac arrest applications, and then we'll move into oncology and all other neurodegenerative diseases. So that's it. Thank you for your time.